登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JAMA，4月3日，Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-06

  • Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers

    Chirag Bavishi, MD, MPH1; Thomas M. Maddox, MD, MSc2,3; Franz H. Messerli, MD4,5,6

    Author Affiliations Article Information

    JAMA Cardiol. Published online April 3, 2020. doi:10.1001/jamacardio.2020.1282

    The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already surpassed the combined mortality inflicted by the severe acute respiratory syndrome (SARS) epidemic of 2002 and 2003 and the Middle East respiratory syndrome (MERS) epidemic of 2013. The pandemic is spreading at an exponential rate, with millions of people across the globe at risk of contracting SARS-CoV-2. Initial reports suggest that hypertension, diabetes, and cardiovascular diseases were the most frequent comorbidities in affected patients, and case fatality rates tended to be high in these individuals. In the largest Chinese study to date,1 which included 44?672 confirmed cases, preexisting comorbidities that had high mortality rates included cardiovascular disease (10.5%), diabetes (7.3%), and hypertension (6.0%). Patients with such comorbidities are commonly treated with renin angiotensin system blockers, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).

  • 原文来源：https://jamanetwork.com/journals/jamacardiology/fullarticle/2764299?resultClick=1
110浏览量
原文链接
相关报告

  • 《Nature，4月3日，Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-04
    • Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic Andrew M. South, Laurie Tomlinson, Daniel Edmonston, Swapnil Hiremath & Matthew A. Sparks Nature Reviews Nephrology (2020) The current COVID-19 pandemic is associated with unprecedented morbidity and mortality. Early reports suggested an association between disease severity and hypertension but did not account for sources of confounding. However, the responsible virus — SARS-CoV-2 — gains entry to host cells via angiotensin-converting enzyme 2 (ACE2), highlighting the need to understand the relationship between the virus and the renin–angiotensin system (RAS) and how this might be affected by RAS inhibitors.
    174浏览量
    原文链接

  • 《NEJM，3月30日，Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-06
    • Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 List of authors. Muthiah Vaduganathan, M.D., M.P.H., Orly Vardeny, Pharm.D., Thomas Michel, M.D., Ph.D., John J.V. McMurray, M.D., Marc A. Pfeffer, M.D., Ph.D., and Scott D. Solomon, M.D. The renin–angiotensin–aldosterone system (RAAS) is an elegant cascade of vasoactive peptides that orchestrate key processes in human physiology. Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and SARS-CoV-2, which have been responsible for the SARS epidemic in 2002 to 2004 and for the more recent coronavirus disease 2019 (Covid-19) pandemic, respectively, interface with the RAAS through angiotensin-converting enzyme 2 (ACE2), an enzyme that physiologically counters RAAS activation but also functions as a receptor for both SARS viruses.1,2 The interaction between the SARS viruses and ACE2 has been proposed as a potential factor in their infectivity,3,4 and there are concerns about the use of RAAS inhibitors that may alter ACE2 and whether variation in ACE2 expression may be in part responsible for disease virulence in the ongoing Covid-19 pandemic.
    152浏览量
    原文链接